Adherium, a digital health platform that focuses on improving medication adherence and patient outcomes, has launched the Hailie solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers.
The Hailie solution is designed to help patients achieve better adherence by providing people who live with asthma or chronic obstructive pulmonary disease (COPD) with the tools to manage their condition. It tracks medication use and reminds the user when it’s time to take doses. It also can provide visibility of medication use and adherence to parents and caregivers.
As part of the platform, Adherium is launching an online portal for healthcare professionals and clinicians to visualize and analyze patient-group data collected from Hailie sensors, enabling the sharing and monitoring of patient inhaler usage.
Asthma continues to be the third-ranking cause of hospitalization for children under 15 years of age in the U.S. It is the leading cause of missed school days among children aged 5 to 17. Students with asthma may be at a higher risk of poor performance, and families continue to struggle to cope with asthma, as each missed day of school can also lead to missed work days.
COPD, characterized by increasing breathlessness, is an umbrella term used to describe progressive lung diseases including emphysema, chronic bronchitis, and refractory (non-reversible) asthma, according to the COPD Foundation. It is progressive and incurable at present, but with the right diagnosis and treatment,can be managed for many years.
Adherium’s has sold more than 130,000 inhaler sensors globally and has been featured in 74 peer-reviewed journals to date.